CAR-T Cell Adjuvant Therapy for Solid Tumor Recurrence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adjuvant treatment strategies for solid tumors, particularly those with high recurrence risk such as liver, gastric, and pancreatic cancers, are inadequate in preventing tumor recurrence and improving patient survival outcomes.
Innovation Solution
An adjuvant treatment method involving the administration of immune cell therapy with chimeric receptors, specifically CAR-T cells and TCR-T cells, targeting tumor-specific antigens such as GPC3, NKG2DL, EpCAM, and B7H3, following local treatment and/or other adjuvant therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adjuvant treatment strategies are used after local treatment, then treatment simplicity is maintained, but tumor recurrence rate increases and patient survival outcomes worsen
Solution Approach 1:
The patent applies self-service by utilizing the patient's own immune system (autologous T cells) that has been genetically modified to recognize and attack tumor antigens. The T cells are harvested from the patient, engineered ex vivo with chimeric receptors, and reinfused to provide long-lasting anti-tumor immunity without requiring external complex treatment protocols
Solution Approach 2:
The patent changes the parameter of T cell specificity by introducing chimeric antigen receptors (CARs) or T cell receptors (TCRs) that recognize specific tumor antigens (GPC3, NKG2DL, EpCAM, B7H3). This transforms generic immune cells into highly specific tumor-targeting effectors, dramatically improving tumor surveillance and recurrence prevention
2Reliability
If conventional adjuvant treatment strategies are used, then treatment simplicity is maintained, but tumor recurrence risk remains high in patients with high recurrence risk
Solution Approach 1:
The patent applies preliminary action by performing tumor antigen identification and T cell engineering before the adjuvant treatment phase. Tumor antigens are identified during or after local treatment, and T cells are engineered ex vivo in advance, allowing for personalized adjuvant therapy that prevents recurrence before it occurs
Solution Approach 2:
The patent applies local quality by tailoring the adjuvant treatment to the specific tumor type and antigen profile of each patient. Different T cell lines (CAR-T or TCR-T) are designed according to the specific tumor characteristics (e.g., GPC3 for liver cancer, NKG2DL for gastric cancer), providing highly localized and effective treatment
3Productivity
If surgery is performed as the main treatment, then tumor resection is achieved, but postoperative recurrence occurs within one year
Solution Approach 1:
The patent applies continuity of useful action by extending the anti-tumor effect beyond the surgical resection. The chimeric receptor T cells continuously circulate in the patient's bloodstream, providing ongoing surveillance and attack of residual tumor cells and micrometastases, thereby preventing recurrence for years rather than just during the immediate postoperative period
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces tumor burden, inhibits recurrence, and prolongs disease-free and overall survival in patients with solid tumors by enhancing immune targeting of cancer cells.
Implementation Method 1
immune cell therapy comprising a chimeric receptor binding to a tumor antigen expressed by the solid tumor
Data Source
AI summary
The present application provides a new adjuvant treatment method for treating tumors, reducing tumor recurrence, inhibiting tumor growth, or inducing tumor necrosis, wherein the method comprises the following: after selecting patients with cancer (for example, liver cancer, pancreatic cancer, gastric cancer, or gastroesophageal junction tumor) in need thereof for tumor local treatment, a therapeutically effective amount of immune cells (for example, CAR-T cells) is administered as a new adjuvant treatment.